LLAI
NEUTRALLungLife AI Provides Regulatory Update
The healthcare company provides an update on regulatory matters.
LLAI
0.00%
Market Cap
Volume
0
NaN% of avg
P/E Ratio
N/A
EPS (TTM)
N/A
Beta
N/A
Day Range
p - p
52 Week Range
N/AppN/Ap
p
Upcoming Events
Q1 2025
Submission of application for Medicare coverage with MolDx
High Impact Event
No data available for this timeframe
LLAI
NEUTRALLungLife AI Announces Change in Major Shareholding
The diagnostics company has announced a change in its major shareholding, with an investor increasing its stake.
LLAI
NEUTRALLungLife AI Announces Holding Changes
The healthcare diagnostics company has reported changes in major shareholdings.
LLAI
NEUTRALLungLife AI Announces Holding Change
The healthcare diagnostics company has announced a change in shareholding.
LLAI
NEUTRALLungLife AI Provides Regulatory Update
The healthcare company provides an update on regulatory matters.
LLAI
NEUTRALLungLife AI Announces Holding Change
The healthcare diagnostics company has reported a change in shareholding, with Cable Car Capital LLC now holding 5.3% of the voting rights.
LLAI
GOODLungLife AI Announces Proposed Cancellation of AIM Listing and Exclusive License Agreement with Circulogene
The diagnostics company has announced plans to cancel its AIM listing and enter an exclusive license agreement with a US-based liquid biopsy firm, providing financial support to continue operations.
LLAI
GOODLungLife AI Secures Exclusive US Distribution Deal for LungLB® Test
The diagnostics company has secured an exclusive US distribution deal for its LungLB® test, providing upfront payments, ongoing royalties, and a potential asset purchase option.
LLAI
NEUTRALLungLife AI Appoints New Nominated Adviser and Joint Broker
The diagnostic company announces the appointment of a new Nominated Adviser and Joint Broker, alongside its existing Joint Broker.
LLAI
BADLungLife AI Proposes AIM Cancellation Amid Funding Challenges
The diagnostic company is proposing to cancel its AIM listing after failing to secure a strategic partner or additional funding to commercialize its lung cancer test.